Literature DB >> 16793841

Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study.

S A Karvounaris1, P I Sidiropoulos, J A Papadakis, E K Spanakis, G K Bertsias, H D Kritikos, E S Ganotakis, D T Boumpas.   

Abstract

OBJECTIVES: Patients with rheumatoid arthritis have an increased risk for cardiovascular disease (CVD). The prevalence of metabolic syndrome (MetS)-a major contributor to CVD-in a cohort of patients with rheumatoid arthritis and its relationship with rheumatoid arthritis related factors is investigated here.
METHODS: 200 outpatients with rheumatoid arthritis (147 women and 53 men), with a mean (standard deviation (SD)) age of 63 (11) years, and 400 age and sex-matched controls were studied. MetS was assessed according to the adult treatment panel III criteria and rheumatoid arthritis disease activity by the disease activity score of 28 joints (DAS28). A standard clinical evaluation was carried out, and a health and lifestyle questionnaire was completed.
RESULTS: The overall prevalence of MetS was 44% in patients with rheumatoid arthritis and 41% in controls (p = 0.5). Patients with rheumatoid arthritis were more likely to have low high-density lipoprotein cholesterol compared with controls (p = 0.02), whereas controls were more likely to have increased waist circumference or raised blood pressure (p = 0.001 and 0.003, respectively). In multivariate logistic regression analysis adjusting for demographics and rheumatoid arthritis treatment modalities, the risk of having moderate-to-high disease activity (DAS28>3.2) was significantly higher in patients with MetS compared with those with no MetS components (OR 9.24, 95% CI 1.49 to 57.2, p = 0.016).
CONCLUSION: A high, albeit comparable to the control population, prevalence of MetS was found in middle-to-older aged patients with rheumatoid arthritis. The correlation of rheumatoid arthritis disease activity with MetS suggests that the increased prevalence of coronary heart disease in patients with rheumatoid arthritis may, at least in part, be attributed to the inflammatory burden of the disease.

Entities:  

Mesh:

Year:  2006        PMID: 16793841      PMCID: PMC1798406          DOI: 10.1136/ard.2006.053488

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis.

Authors:  Patrick H Dessein; Barry I Joffe; Anne Stanwix; Andre S Botha; Zubair Moomal
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

3.  Comorbidity in arthritis.

Authors:  S E Gabriel; C S Crowson; W M O'Fallon
Journal:  J Rheumatol       Date:  1999-11       Impact factor: 4.666

4.  Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis.

Authors:  A McEntegart; H A Capell; D Creran; A Rumley; M Woodward; G D Lowe
Journal:  Rheumatology (Oxford)       Date:  2001-06       Impact factor: 7.580

5.  Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study.

Authors:  Robert M Najarian; Lisa M Sullivan; William B Kannel; Peter W F Wilson; Ralph B D'Agostino; Philip A Wolf
Journal:  Arch Intern Med       Date:  2006-01-09

Review 6.  Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Authors:  Brent A Neuschwander-Tetri; Stephen H Caldwell
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

7.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

8.  Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study.

Authors:  Anthony J G Hanley; Andrew J Karter; Andreas Festa; Ralph D'Agostino; Lynne E Wagenknecht; Peter Savage; Russell P Tracy; Mohammed F Saad; Steven Haffner
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

9.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

Authors:  Haiyan Xu; Glenn T Barnes; Qing Yang; Guo Tan; Daseng Yang; Chieh J Chou; Jason Sole; Andrew Nichols; Jeffrey S Ross; Louis A Tartaglia; Hong Chen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

10.  Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis.

Authors:  Patrick H Dessein; Anne E Stanwix; Barry I Joffe
Journal:  Arthritis Res       Date:  2002-06-19
View more
  49 in total

1.  [Diabetes and rheumatism: is diabetes mellitus also an inflammatory disease?].

Authors:  S Graf; P-M Schumm-Draeger
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

Review 2.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

3.  Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis.

Authors:  Monalyn Labitigan; Asena Bahče-Altuntas; Joel M Kremer; George Reed; Jeff D Greenberg; Nicole Jordan; Chaim Putterman; Anna Broder
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

4.  Prevalence of the metabolic syndrome in rheumatoid arthritis.

Authors:  Mustafa Özmen; Özlem Yersal; Serpil Öztürk; Dilek Soysal; Mehmet Hicri Köseeoğlu
Journal:  Eur J Rheumatol       Date:  2014-03-01

5.  Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy.

Authors:  Linda A Feagins; Avegail Flores; Cristina Arriens; Christina Park; Terri Crook; Andreas Reimold; Geri Brown
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-10       Impact factor: 2.566

6.  A comparative analysis of serological parameters and oxidative stress in osteoarthritis and rheumatoid arthritis.

Authors:  Rachana Mishra; Aastha Singh; Vishal Chandra; Mahendra P S Negi; Baishnab C Tripathy; Jaya Prakash; Varsha Gupta
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 7.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

9.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

10.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.